What jscreen does

jscreen (legal entity JScreen.Org, Inc., Delaware-incorporated) is a national nonprofit founded in 2013 and headquartered in Atlanta, Georgia, that operates a direct-to-consumer at-home genetic testing program for adults in the United States. Its core products are the Reproductive Carrier Screen (a saliva-based panel covering over 260 inherited conditions including Tay-Sachs, cystic fibrosis, sickle cell disease, and conditions more prevalent in the Ashkenazi Jewish population), the Hereditary Cancer Test (a 63-gene panel including BRCA1 and BRCA2), and a Combo Bundle combining both screens; it also offers jGift, a gift-card channel for the same tests. The company was initially established to serve the Jewish community and has subsequently broadened its reach to additional at-risk populations while retaining Ashkenazi-specific content and community partnerships.

Operationally, jscreen runs an asset-light model: customers self-register online, saliva collection kits are mailed and returned under a pre-paid label, and laboratory processing is performed by Myriad Genetics in its certified facility. Physician ordering and review are handled via DNAvisit, and every test includes access to telehealth genetic counseling and care navigators. Pricing is hybrid—insurance billing with a $39 upfront patient payment, or self-pay at $249–$298 for a single test and $567 for the combo bundle—with reported out-of-pocket costs of $0 for over 90% of hereditary cancer customers through insurance coverage and financial assistance.

Go-to-market is direct e-commerce (jscreen.org) supported by digital content marketing, organic social, and earned media, supplemented by community-event channels in partnership with organizations such as Manischewitz and the Mathew Forbes Romer Foundation. The company accepts more than 200 commercial and government insurance plans and is HIPAA-compliant; geographic service is limited to the United States. With only 1–10 disclosed employees and no reported funding rounds, jscreen operates as a small, mission-driven nonprofit whose competitive position rests on community trust, culturally targeted outreach, and integrated clinical support rather than scale.

Name

jscreen

Legal name

JScreen.Org, Inc.

Website

https://jscreen.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

jscreen is a US national nonprofit that sells direct-to-consumer, at-home saliva-based genetic screening for reproductive carrier status (260+ conditions) and hereditary cancer risk (63 genes including BRCA1/2), with telehealth genetic counseling included on every order. It originated serving the Ashkenazi Jewish community and now serves broader at-risk populations via insurance-billing or self-pay.

Ownership category

akta.pro rank

Product category

Direct-to-Consumer Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• At-home genetic testing
• Reproductive carrier screening
• Hereditary cancer testing
• Telehealth genetic counseling
• Jewish genetic disease screening

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Genetic Testing Services: One-time genetic testing fees with upfront patient payment ($39-$49) plus insurance billing or self-pay options ($249-$298 for full self-pay). Insurance covers most costs for eligible patients, with many paying $0 out-of-pocket.
2. Combo/Bundle Testing: Combined reproductive carrier and hereditary cancer testing offered as a bundle at discounted pricing ($69 upfront with insurance billing, $567 for full self-pay).
3. Gift Cards (jGift): Gift cards for genetic testing purchased by consumers to give to friends and family members. Options range from $49-$567 depending on test type and self-pay vs insurance billing.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

jscreen is a national nonprofit that provides at-home saliva-based genetic testing services for reproductive carrier screening (covering 260+ inherited conditions) and hereditary cancer risk assessment (covering 63 genes including BRCA1/BRCA2). Tests are sold direct-to-consumer via jscreen.org without a doctor's referral, paired with telehealth genetic counseling and care navigation delivered by partner physicians and certified genetic counselors. Lab processing is performed by Myriad Genetics, and the service accepts both insurance billing and self-pay options.

Product overview

jscreen is a national nonprofit organization offering at-home genetic testing for cancer and reproductive health. The core product portfolio consists of three main genetic screening tests: the Reproductive Carrier Screen (testing for 260+ inherited conditions), the Hereditary Cancer Test (screening 63 cancer-associated genes including BRCA1/BRCA2), and their Combo Bundle combining both tests. The company also offers jGift, a gift card service for gifting genetic testing. All tests include at-home saliva collection, physician-ordered testing, and telehealth genetic counseling. jscreen primarily serves the Ashkenazi Jewish community while expanding to serve broader populations.

Differentiator

Problem solved

Functional benefit

Brands

• jGift: A gift card program allowing people to gift genetic testing services (reproductive carrier screening and hereditary cancer testing) to friends and family members.

Products and services

• Reproductive Carrier Screen At-home saliva-based genetic test that identifies individuals and couples at risk of passing inherited conditions to their children. Screens for over 260 diseases including Tay-Sachs, cystic fibrosis, sickle cell anemia, and Ashkenazi Jewish genetic conditions. Designed for people who are pregnant, planning pregnancy, or trying to conceive. Includes physician-ordered testing, telehealth genetic counseling, and care navigation.
• Hereditary Cancer Test At-home genetic test that screens 63 genes associated with hereditary cancer risk, including BRCA1 and BRCA2. Provides actionable results and a personalized care plan to support proactive health management. Includes physician-ordered testing, telehealth genetic counseling, and care navigation.
• Combo Test (Carrier + Cancer) Bundled package that combines the Reproductive Carrier Screen and the Hereditary Cancer Test, providing comprehensive genetic health information for individuals and couples making family planning and health decisions. Includes physician-ordered testing, telehealth genetic counseling, and care navigation.
• jGift Gift card service that lets users purchase and gift genetic testing kits to friends and family members. Recipients redeem unique codes for reproductive carrier screening and/or hereditary cancer testing including at-home kits and genetic counseling. Gift card prices range from $49 to $567 depending on test selection and self-pay versus insurance billing.

Quantifiable outcome

• Over 90% of customers pay nothing out-of-pocket for hereditary cancer testing through insurance coverage and financial assistance
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship, minor and core.

• ManischewitzflagshipStrategic or Co-development Partner · 2 February 2026JScreen and Manischewitz kosher-food company partnered to host community-based cancer genetic testing and education events in New York City during Cancer Prevention Month in February 2026. Events included screening for hereditary cancers and reproductive carrier conditions at MMJCCM and Yeshiva University locations.
• Gila PfefferminorStrategic or Co-development Partner · 30 January 2026Author and cancer advocate partnering with jscreen and Manischewitz to host community genetic testing events for Cancer Prevention Month in New York City.
• Mathew Forbes Romer FoundationflagshipStrategic or Co-development Partner · 19 December 2025Multi-year partnership expanded to bring genetic education, screening, and testing resources to South Florida communities. Partnership includes community events such as the 2nd Annual MFRF 'Brain Health Hustle' 5K Walk/Run and genetic testing events offering reproductive carrier screening and hereditary cancer screening for conditions including Tay-Sachs, cystic fibrosis, and BRCA genes.
• Myriad GeneticscoreTechnology or IntegrationMyriad Genetics processes genetic testing samples for jscreen. They send saliva collection kits to customers and analyze samples in their certified laboratory. Myriad also provides cost estimates and handles insurance billing for tests.
• DNAvisitcoreImplementation/ SI/ Consulting PartnerDNAvisit provides physician review and test ordering services for jscreen's genetic testing program. They facilitate the medical oversight required for ordering genetic tests.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Natera: Natera offers reproductive and oncology genetic testing including carrier screening and hereditary cancer panels, often with employer and patient-direct channels. Comparable to jscreen as it competes in expanded carrier screening and hereditary cancer risk testing sold to consumers and through clinical channels.
• 23andMe: 23andMe is a leading direct-to-consumer genetic testing company offering at-home saliva kits for ancestry, health predispositions (including BRCA-related reports), and carrier status. It is comparable to jscreen because it sells DTC saliva-based genetic screening to consumers without a doctor's order, competing for the same end customer with overlapping product categories (carrier screening, hereditary cancer risk).
• Color Health: Color provides clinical and direct-to-consumer genetic testing for hereditary cancer risk (including BRCA1/BRCA2), carrier screening, and pharmacogenomics, with included genetic counselors. Directly comparable to jscreen because it overlaps on hereditary cancer panels, carrier screening, and bundled genetic counseling support.
• AncestryDNA: AncestryDNA sells DTC at-home saliva collection genetic tests directly to consumers, primarily focused on ancestry but with health add-ons through AncestryHealth. Comparable to jscreen as a DTC saliva kit workflow competing for similar consumer mind-share on family health and genetic insights.

Broad incumbents

• Myriad Genetics: Myriad Genetics is jscreen's laboratory partner and a global leader in hereditary cancer testing (BRACAnalysis, myRisk) and reproductive carrier screening (Foresight). It is jscreen's lab and a broader incumbent whose products and direct-to-consumer initiatives compete in the same tests jscreen resells.
• Invitae: Invitae (now part of Labcorp) is a major clinical genetics company offering hereditary cancer testing, reproductive carrier screening, and proactive health panels. Comparable to jscreen as it provides the same panel-based genetic tests and competes for the same proactive-screening end consumer via clinical and increasingly direct channels.
• Quest Diagnostics (Hereditary & Carrier Testing): Quest Diagnostics offers hereditary cancer and carrier screening tests through its patient-direct and provider channels (e.g., Quest's genetic testing services). Comparable to jscreen as a large incumbenta competing in the same hereditary cancer and reproductive carrier testing categories, though typically through provider ordering rather than pure DTC.
• GeneDx: GeneDx (formerly Sema4) provides clinical genetic testing across hereditary cancer, rare disease, and reproductive health, including carrier screening. It overlaps with jscreen on expanded carrier panels and hereditary cancer testing, but operates more through clinical/provider channels than pure DTC.

Emerging players

• Helix: Helix operates a next-generation sequencing platform powering DTC and population health genetic products, including carrier screening applications. Comparable to jscreen because it serves the at-home genetic screening use case with a model that combines lab infrastructure and consumer-facing products.
• Jax (The Jackson Laboratory for Genomic Medicine): The Jackson Laboratory is a nonprofit biomedical research institute with clinical genomic services for hereditary cancer and rare disease. Comparable to jscreen as a mission-driven, nonprofit-adjacent organization offering clinical genetic testing and counseling, though with a stronger research and rare disease orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/myjscreen
• YouTubeyoutube.com/user/MyJScreen
• Facebookfacebook.com/myjscreen
• LinkedInlinkedin.com/company/jscreen
• Instagraminstagram.com/getjscreened

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about jscreen